News: ResApp Health expands clinical study for respiratory diagnostic technology

ResApp Health (ASX:RAP), formerly Narhex Life Sciences has expanded a clinical study to commercialise its mobile medical applications for the diagnosis and management of respiratory diseases adding a second site for enrolling patients.

Approval has been gained to enrol the first patient at Princess Margaret Hospital in Perth.

The technology has been tested for pneumonia and asthma diagnosis in a clinical proof of concept study of 91 patients by University of Queensland through funding from the Bill and Melinda Gates Foundation.

The technology is based on a machine learning algorithm that uses sound alone to diagnose and measure the severity of a respiratory condition.

The company holds an exclusive licence from the University of Queensland to develop and commercialise mobile medical applications for the diagnosis and management of respiratory diseases.

The addition to the clinical study adds to the existing study currently underway at Joondalup Health Campus that has enrolled more than 150 patients.

The study will gather data from patients with a variety of respiratory conditions to further optimise the ResApp algorithms for pneumonia and asthma.

ResApp is now working with the University of Queensland to analyse the data and expects to receive initial preliminary results in Q3 2015.

The company is looking at a range of services from the technology to generate revenues streams.

ResApp re-commenced trading on the Australian Securities Exchange in July after successfully raising $4 million at $0.20 per share.

Shares in RAP are currently trading at $0.023.